Registration number:
for the
Year Ended 31 March 2025
Summit Medical Limited
Contents
|
Company Information |
|
|
Directors' Report |
|
|
Strategic Report |
|
|
Statement of Directors' Responsibilities |
|
|
Independent Auditor's Report |
|
|
Profit and Loss Account |
|
|
Balance Sheet |
|
|
Statement of Changes in Equity |
|
|
Notes to the Financial Statements |
Summit Medical Limited
Company Information
|
Directors |
C P Lee A J Simpson |
|
Registered office |
|
|
Auditors |
|
Summit Medical Limited
Directors' Report for the Year Ended 31 March 2025
The directors present their report and the financial statements for the year ended 31 March 2025.
Directors of the company
The directors who held office during the year were as follows:
Financial instruments
Objectives and policies
The board constantly monitors the company's trading results and revise projections as appropriate to ensure that the company can meet its future obligations as they fall due.
Price risk, credit risk, liquidity risk and cash flow risk
The company is exposed to the usual credit and cash flow risks associated with selling on credit and manages this through credit control procedures.
Future developments
It is believed that continued investment in developing both new products and enhancing existing products, together with particular emphasis on quality, design and customer service will enable the business to maintain and build on its market position.
Going concern
The company's ability to continue to be a going concern is linked to ability of the wider Summit Medical Group headed by the Company's ultimate parent Bowmoor Topco Limited.
The directors have prepared forecasts for the next 12 months that indicate that cash flows will be sufficient for the company to meet its financing commitments as they fall due. The directors therefore have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and have continued to adopt the going concern basis in preparing the financial statements.
Further detail of the directors assessment of going concern can be found in the accounting policy disclosed in note 2.
Disclosure of information to the auditors
Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.
Reappointment of auditors
Hazlewoods LLP have expressed their willingness to continue in office.
Approved by the
Director
Summit Medical Limited
Strategic Report for the Year Ended 31 March 2025
The directors present their strategic report for the year ended 31 March 2025.
Principal activity
The principal activity of the company is the production and sale of medical devices.
Fair review of the business
The results for the year, which are set out in the profit and loss account, show turnover of £15,908,083 (2024 - £17,398,834) and an operating profit of £1,153,047 (2024 - £2,118,817). At 31 March 2025, the company had net assets of £22,126,854 (2024 - £23,581,840). The directors consider the performance for the year and the financial position at the year end to be satisfactory.
The directors have monitored the company's performance against the overall group strategy by reference to certain financial key performance indicators. The targets set for each year are challenging and the directors are satisfied that, in the current economic climate, the performance of the company is solid. Key performance indicators include turnover, gross profit and operating profit which are shown in the profit and loss account.
Principal risks and uncertainties
The management of the business and the execution of the company's strategy are subject to a number of risks. The key business risks and uncertainties affecting the company are considered to relate to ongoing compliance with current and future legislation affecting the sector.
Approved by the
Director
Summit Medical Limited
Statement of Directors' Responsibilities
The directors are responsible for preparing the Directors' Report, Strategic Report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
• | select suitable accounting policies and apply them consistently; |
• | make judgements and accounting estimates that are reasonable and prudent; |
• | state whether applicable UK Accounting Standards has been followed, subject to any material departures disclosed and explained in the financial statements; and |
• | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Summit Medical Limited
Independent Auditor's Report to the Members of Summit Medical Limited
Opinion
We have audited the financial statements of Summit Medical Limited (the 'company') for the year ended 31 March 2025, which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
• | give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its loss for the year then ended; |
• | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
• | have been prepared in accordance with the requirements of the Companies Act 2006. |
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Other information
The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Summit Medical Limited
Independent Auditor's Report to the Members of Summit Medical Limited
Opinion on other matter prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
|
• |
the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
|
• |
the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements. |
Matters on which we are required to report by exception
In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
• | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or |
• | the financial statements are not in agreement with the accounting records and returns; or |
• | certain disclosures of directors' remuneration specified by law are not made; or |
• | we have not received all the information and explanations we require for our audit. |
Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
We considered the nature of the company’s industry and its control environment and reviewed the company’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.
We obtained an understanding of the legal and regulatory framework that the company operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty.
We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.
Summit Medical Limited
Independent Auditor's Report to the Members of Summit Medical Limited
In common with all audits conducted in accordance with ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.
In addition to the above, our procedures to respond to the risks identified included the following:
|
• |
reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements; |
|
• |
performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud; |
|
• |
enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and |
|
• |
reading minutes of meetings of those charged with governance. |
Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.
A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
For and on behalf of
Windsor House
Bayshill Road
GL50 3AT
Summit Medical Limited
Profit and Loss Account for the Year Ended 31 March 2025
|
Notes |
2025 |
2024 |
|
|
Turnover |
|
|
|
|
Cost of sales |
( |
( |
|
|
Gross profit |
|
|
|
|
Distribution costs |
( |
( |
|
|
Administrative expenses |
( |
( |
|
|
Operating profit |
|
|
|
|
Other interest receivable and similar income |
|
|
|
|
Interest payable and similar charges |
( |
( |
|
|
(Loss)/profit before tax |
( |
|
|
|
Taxation |
( |
( |
|
|
(Loss)/profit for the financial year |
( |
|
The above results were derived from continuing operations.
The company has no recognised gains or losses for the year other than the results above.
Summit Medical Limited
(Registration number: 04193536)
Balance Sheet as at 31 March 2025
|
Notes |
2025 |
2024 |
|
|
Fixed assets |
|||
|
Intangible assets |
|
|
|
|
Tangible assets |
|
|
|
|
Investments |
|
|
|
|
|
|
||
|
Current assets |
|||
|
Stocks |
|
|
|
|
Debtors: Amounts falling due within one year |
3,616,265 |
3,297,681 |
|
|
Debtors: Amounts falling due after more than one year |
42,238,430 |
41,596,880 |
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets |
|
|
|
|
Total assets less current liabilities |
|
|
|
|
Creditors: Amounts falling due after more than one year |
( |
( |
|
|
Provisions for liabilities |
( |
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Share premium reserve |
|
|
|
|
Capital redemption reserve |
|
|
|
|
Profit and loss account |
|
|
|
|
Total equity |
|
|
Approved and authorised by the
Director
Summit Medical Limited
Statement of Changes in Equity for the Year Ended 31 March 2025
|
Share capital |
Share premium |
Capital redemption reserve |
Profit and loss account |
Total |
|
|
At 1 April 2024 |
|
|
|
|
|
|
Loss for the year |
- |
- |
- |
( |
( |
|
At 31 March 2025 |
|
|
|
|
|
|
Share capital |
Share premium |
Capital redemption reserve |
Profit and loss account |
Total |
|
|
At 1 April 2023 |
|
|
|
|
|
|
Profit for the year |
- |
- |
- |
|
|
|
At 31 March 2024 |
|
|
|
|
|
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
General information |
The company is a private company limited by share capital, incorporated in England and Wales.
The address of its registered office is:
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.
Basis of preparation
These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.
The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.
Name of parent of group
These financial statements are consolidated in the financial statements of Bowmoor Topco Limited.
The financial statements of Bowmoor Topco Limited may be obtained from Companies House.
Group accounts not prepared
Going concern
The company is part of the group banking facility. The financial statements have been prepared on a going concern basis. In assessing the appropriateness of this basis, the Directors have considered the Group’s financial position, available facilities and forecast cash flows for a period of at least 12 months from the date of approval of these financial statements.
The Group experienced covenant breaches and missed debt service payments post year end. These breaches were formally waived by lenders and, on 7 May 2026, the Group entered into an amended and restated banking facility agreement, which formalised the waivers and revised the terms of the Group’s financing arrangements.
The Directors have prepared cash flow forecasts and covenant compliance projections under the revised facility. These forecasts include assumptions regarding trading performance, cash generation and working capital movements and have been subject to sensitivity analysis to reflect reasonably possible downside scenarios.
The Directors have assessed the impact of these scenarios on the Group’s liquidity and compliance with its financial covenants, which require an improvement in financial performance when compared to the results over the past two years. Whilst the assessment requires the exercise of judgement, the Directors consider the assumptions applied to be reasonable and supportable and note that the Group is expected to maintain adequate liquidity and remain in compliance with its covenants throughout the assessment period.
Accordingly, the Directors conclude that it is appropriate to adopt the going concern basis of accounting in preparing these financial statements and that no material uncertainty related to going concern has been identified.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
Changes in accounting policy
The following have been applied for the first time from 1 April 2024 and have had an effect on the financial statements:
Early Adoption of Amendments to FRS102
The company has chosen to early adopt the amendments to FRS 102 issued in September 2024.
The amendments to FRS 102 have revised the accounting for leases and revenue recognition where the Company has opted to apply the practical expedient under paragraph 1.48 to all of its leases which has had the following impact;
Right of use assets as at 31 March 2025 - £825,355 (on transition as at 1 April 2024 - £927,295)
Lease Liabilities as at 31 March 2025 - £861,673 (on transition as at 1 April 2024 - £927,295)
Impact to profit and loss account for the period 1 April 2024 to 31 March 2025 - loss of £36,318
The amendments to FRS 102 have introduced changes to revenue recognition policies and fair value measurement requirements. The company has early adopted these amendments with them having no impact on the financial statements.
Judgements
Preparation of the financial statements requires management to make significant judgements and estimates. The main item in the financial statements where these judgements have been applied is capitalised development costs. |
Revenue recognition
In line with the companies application for early adoption of the amendments to FRS 102, the revenue recognition model for accounting has been amended to revenue from contracts with customers and applies the five step model to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods and services. Revenue from contracts with customers is shown net of value added tax, returns, rebates and discounts and after eliminating sales within the company.
There are five steps involved in applying this model:
•Step 1: Identify the contract(s) with a customer
•Step 2: Identify the performance obligations in the contract
•Step 3: Determine the transaction price
•Step 4: Allocate the transaction price to the performance obligations in the contract; and
•Step 5: Recognise revenue when (or as) the entity satisfies a performance obligation
Accordingly there was no material change in revenue recognition due to the transition to the five step model.
Foreign currency transactions and balances
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.
Tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Freehold property |
Straight line over 50 years |
|
Leasehold improvements |
Over the term of the lease |
|
Plant and machinery |
Between 20% and 33.33% straight line |
|
Fixtures and fittings |
20% straight line |
|
Computer equipment |
20% straight line |
|
Hardware |
50% straight line |
Intangible assets
Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.
Patents are initially measured at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Development costs are recognised as an intangible asset when a number of criteria are demonstrated. These are the technical feasibility of completing the product so that it will be available for use or sale, the intention to complete the product and use or sell it, the ability to use the product or sell it, how the product will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and to use or sell the product and the ability to measure reliably the expenditure attributable to the product during development.
Amortisation
Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:
|
Asset class |
Amortisation method and rate |
|
Patents |
Straight line over 5 years |
|
Development expenditure |
Over useful life from launch of product |
|
Goodwill |
Straight line over 20 years |
Investments
Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.
Borrowings
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
Leases
Short term leases (up to one year) or leases of low value (up to £500) are recognised as an expense on a straight-line basis over the term of the lease.
The Group recognises right-of-use assets under lease agreements in which it is the lessee. The underlying assets comprise property, plant and machinery and motor vehicles, and are used in the normal course of business. The right-of-use assets comprise the initial measurement of the corresponding lease liability payments made at or before the commencement day as well as any initial direct costs and an estimate of costs to be incurred in dismantling the asset. Lease incentives are deducted from the cost of the right-of-use asset. The corresponding lease liability is included in the statement of financial position as a lease liability.
The right-of-use asset is depreciated on a straight-line basis over shorter of the asset’s useful life and the lease term and where impairment indicators exist, the right of use asset will be assessed for impairment.
The lease liability shall initially be measured at the present value of the lease payments that are not paid at that date, discounted using the rate implicit in the lease or, where this cannot be determined, the Group’s incremental borrowing rate. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (application of the effective interest method) and by reducing the carrying amount to reflect the lease payments made. No lease modification or reassessment changes have been made during the reporting period from changes in any lease terms or rent charges.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Defined contribution pension obligation
A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
Financial instruments
Classification
Recognition and measurement
Impairment
A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.
The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.
Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.
For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.
For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.
Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Revenue |
The analysis of the company's Turnover for the year from continuing operations is as follows:
|
2025 |
2024 |
|
|
Rendering of services |
|
|
The analysis of the company's turnover for the year by market is as follows:
|
2025 |
2024 |
|
|
United Kingdom |
|
|
|
Rest of Europe |
|
|
|
Rest of world |
|
|
|
|
|
|
Operating profit |
Arrived at after charging:
|
2025 |
2024 |
|
|
Depreciation expense |
|
|
|
Amortisation expense |
|
|
|
Foreign exchange losses |
|
|
|
Lease payments |
- |
|
|
Other interest receivable and similar income |
|
2025 |
2024 |
|
|
Interest receivable from group companies |
509,148 |
986,398 |
|
Interest payable and similar expenses |
|
2025 |
2024 |
|
|
Bank interest payable |
1,781,934 |
226,942 |
|
Interest payable to group companies |
|
|
|
Right-of-use lease interest expense |
93,604 |
- |
|
Amortisation of debt costs |
|
|
|
|
|
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Staff costs |
The aggregate payroll costs (including directors' remuneration) were as follows:
|
2025 |
2024 |
|
|
Wages and salaries |
|
|
|
Social security costs |
|
|
|
Pension costs, defined contribution scheme |
|
|
|
|
|
Directors remuneration has been borne by another group company.
The average number of persons employed by the company (including directors) during the year, analysed by category was as follows:
|
2025 |
2024 |
|
|
Production |
|
|
|
Selling and distribution |
|
|
|
Administration |
|
|
|
Management |
|
|
|
|
|
|
Auditors' remuneration |
|
2025 |
2024 |
|
|
Fees payable to the Company's auditor for the audit of the Group's annual accounts |
|
|
|
Other fees to auditors |
||
|
Taxation compliance services |
|
|
|
Other non audit related services |
|
|
|
|
|
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Taxation |
Tax charged/(credited) in the profit and loss account
|
2025 |
2024 |
|
|
Current taxation |
||
|
UK corporation tax adjustment to prior periods |
- |
|
|
Deferred taxation |
||
|
Arising from origination and reversal of timing differences |
|
|
|
Tax expense in the income statement |
|
|
The tax on profit before tax for the year is lower than the standard rate of corporation tax in the UK (2024 - lower than the standard rate of corporation tax in the UK) of
The differences are reconciled below:
|
2025 |
2024 |
|
|
(Loss)/profit before tax |
( |
|
|
Corporation tax at standard rate |
( |
|
|
Tax increase from effect of capital allowances and depreciation |
|
|
|
Effect of expense not deductible in determining taxable profit (tax loss) |
|
|
|
Tax increase/(decrease) arising from group relief |
|
( |
|
Increase in UK and foreign current tax from unrecognised temporary difference from a prior period |
- |
|
|
Deferred tax expense/(credit) relating to changes in tax rates or laws |
|
( |
|
Tax increase from effect of adjustment in research and development tax credit |
|
- |
|
Total tax charge |
|
|
Deferred tax
Deferred tax assets and liabilities
|
2025 |
Liability |
|
Accelerated capital allowances |
|
|
Losses |
( |
|
Short term timing differences |
( |
|
|
|
2024 |
Liability |
|
Accelerated capital allowances |
|
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Intangible assets |
|
Goodwill |
Patents |
Development |
Total |
|
|
Cost |
||||
|
At 1 April 2024 |
|
|
|
|
|
Additions |
- |
- |
|
|
|
At 31 March 2025 |
|
|
|
|
|
Amortisation |
||||
|
At 1 April 2024 |
|
|
|
|
|
Amortisation charge |
- |
|
|
|
|
At 31 March 2025 |
|
|
|
|
|
Carrying amount |
||||
|
At 31 March 2025 |
|
|
|
|
|
At 31 March 2024 |
|
|
|
|
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Tangible assets |
|
Freehold property |
Tangible Development |
Plant and machinery |
Fixtures and fittings |
Hardware |
Right of use assets |
Total |
|
|
Cost |
|||||||
|
At 1 April 2024 |
|
|
|
|
|
- |
|
|
On transition to early adoption of amendments to FRS102 |
- |
- |
- |
- |
- |
|
|
|
Additions |
|
|
|
|
|
|
|
|
At 31 March 2025 |
|
|
|
|
|
|
|
|
Depreciation |
|||||||
|
At 1 April 2024 |
|
|
|
|
|
- |
|
|
Charge for the year |
|
|
|
|
|
|
|
|
At 31 March 2025 |
|
|
|
|
|
|
|
|
Carrying amount |
|||||||
|
At 31 March 2025 |
|
|
|
|
|
|
|
|
At 31 March 2024 |
|
|
|
|
|
- |
|
The amendments to FRS 102 have revised the accounting for leases. The company has early adopted these amendments, leading to the recognition of right of use assets with a net book value of £927,295 as at 1 April 2024 and subsequently £825,355 as at 31 March 2025. Right of use assets relate to freehold properties and motor vehicles which the company leases for use in its operations.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Investments |
|
2025 |
2024 |
|
|
Investments |
|
|
|
Subsidiaries |
£ |
|
Cost and carrying amount |
|
|
At 1 April 2024 and at 31 March 2025 |
|
Details of undertakings
Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:
|
Undertaking |
Registered office |
Holding |
Proportion of voting rights and shares held |
|
|
2025 |
2024 |
|||
|
Subsidiary undertakings |
||||
|
|
Ordinary |
|
|
|
|
England and Wales |
||||
|
|
Ordinary |
|
|
|
|
England and Wales |
||||
|
|
Ordinary |
|
|
|
|
England and Wales |
||||
|
|
Ordinary |
|
|
|
|
England and Wales |
||||
|
|
Ordinary |
|
|
|
|
England and Wales |
||||
|
Subsidiary undertakings |
|
Summit Medical UK Limited The principal activity of Summit Medical UK Limited is |
|
Marlux Medical Limited The principal activity of Marlux Medical Limited is |
|
Summit Medical (Benefits) Limited The principal activity of Summit Medical (Benefits) Limited is |
|
Orthodesign Limited The principal activity of Orthodesign Limited is |
|
Marshall Contracts Limited The principal activity of Marshall Contracts Limited is |
The registered office address of all subsidiaries is Bourton Industrial Park, Bourton-On-The-Water, Cheltenham, England, GL54 2HQ.
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Stocks |
|
2025 |
2024 |
|
|
Raw materials and consumables |
|
|
|
Work in progress |
|
|
|
Finished goods and goods for resale |
|
|
|
|
|
|
Debtors |
|
2025 |
2024 |
|
|
Trade debtors |
|
|
|
VAT |
- |
|
|
Prepayments |
|
|
|
Amounts owed by group undertakings |
42,238,430 |
41,596,880 |
|
|
|
|
|
Less non-current portion |
( |
( |
|
Total current trade and other debtors |
|
|
Details of non-current trade and other debtors
£42,238,430 (2024 - £41,596,880) of amounts owed by group undertakings included within receivables from related parties is classified as non current.
|
Creditors |
|
Note |
2025 |
2024 |
|
|
Due within one year |
|||
|
Loans and borrowings |
|
- |
|
|
Trade creditors |
|
|
|
|
Social security and other taxes |
|
|
|
|
Other creditors |
|
|
|
|
Accrued expenses |
|
|
|
|
|
|
||
|
Due after one year |
|||
|
Loans and borrowings |
|
|
|
|
Amounts owed to group undertakings |
22,521,456 |
20,855,900 |
|
|
37,184,543 |
34,666,297 |
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Loans and borrowings |
Current loans and borrowings
|
2025 |
2024 |
|
|
Lease liabilities |
|
- |
Non-current loans and borrowings
|
2025 |
2024 |
|
|
Bank borrowings |
|
|
|
Lease liabilities |
|
- |
|
|
|
|
Total bank debt at 31 March 2025 gross of capitalised debt costs was £14,514,974 (2024 - £14,519,271).
As at the year end, the total bank loan facility available was split into four facilities. Facility A of the bank loan amounting to £3,437,500 is repayable in full as a bullet payment in February 2028. Interest is levied at a rate of 6.75% over base rate. Facility B1 of the bank loan amounting to £5,312,500 is repayable in full as a bullet payment in February 2028. Interest is levied at a rate of 6.75% over base rate. Facility B2 of the bank loan amounting to £5,000,000 is repayable in full as a bullet payment in February 2028. Interest is levied at a rate of 7.00% over base rate. The final facility available is a £2,000,000 revolving cash facility, of which £700,000 is drawn at the balance sheet date, and is repayable in full in February 2028 and attracts interest at a levied rate of 6.75% over base rate. These debt facilities were updated after the balance sheet date as disclosed in note 23.
The above loans are secured by way of a debenture including a fixed mortgage charge over all property and a fixed first charge over all assets of the group, excluding assets held by Bowmoor Topco Limited directly, as well as an additional floating charge over all assets both present and future of the group, excluding those held by Bowmoor Topco Limited directly.
The amendments to FRS 102 have revised the accounting for leases. The company has early adopted these amendments, leading to the recognition of lease liabilities with a carrying value of £927,295 on transition as at 1 April 2024 and subsequently £861,673 as at 31 March 2025. Interest of £93,604 has been recognised for the period 1 April 2024 to 31 March 2025 using an interest rate of 11% with a cash outflow for the same period of £257,670. A lease liability of £186,301 is due within one year and £675,372 is due in 1-5 years. See note 2 for more details.
|
Pension and other schemes |
Defined contribution pension scheme
The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £
Contributions totalling £Nil (2024 - £Nil) were payable to the scheme at the end of the year.
|
Share capital |
Allotted, called up and fully paid shares
|
2025 |
2024 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
9,851 |
|
9,851 |
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Reserves |
Share premium
Includes any premiums received in issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium.
Capital redemption reserve
Represents the amount that the company has transferred from the profit and loss account and is required to retain as a result of repurchasing its own shares. It is a non-distributable reserve.
Profit and loss account
Includes all current and prior periods retained profits and losses.
|
Obligations under leases and hire purchase contracts |
Finance leases
The total of future minimum lease payments is as follows:
|
2025 |
2024 |
|
|
Not later than one year |
|
- |
|
Later than one year and not later than five years |
|
- |
|
Later than five years |
|
- |
|
|
- |
Operating leases
The total of future minimum lease payments is as follows:
|
2025 |
2024 |
|
|
Not later than one year |
- |
|
|
Later than one year and not later than five years |
- |
|
|
Later than five years |
- |
|
|
- |
|
The amendments to FRS 102 have revised the accounting for leases. The company has early adopted these amendments, leading to there being £nil operating leases as at 31 March 2025 with these instead being included in the lease liabilities note. See note 2 for more details.
|
Contingent liabilities |
At 31 March 2025, there was an unlimited cross-guarantee between OrthoD Midco Limited, Summit Medical Limited, Summit Medical UK Limited and Marlux Medical Limited in favour of TC Loans Limited. The amount guaranteed is £14,450,000 (2024 - £14,450,000).
Summit Medical Limited
Notes to the Financial Statements for the Year Ended 31 March 2025
|
Financial instruments |
Categorisation of financial instruments
|
2025 |
2024 |
|
|
Financial assets measured at amortised cost through profit or loss |
|
|
|
Financial liabilities measured at amortised cost through profit or loss |
|
|
Financial assets measured at amortised cost comprise cash, trade debtors, amounts owed by group undertakings and other debtors at year end.
Financial liabilities measured at amortised cost comprise trade creditors, amounts owed to group undertakings, other creditors and accrued expenses at year end.
|
Non adjusting events after the financial period |
After the balance sheet date, the Company refinanced its debt facilities with its current lender. The Company also entered into a sale and leaseback arrangement in respect of the Bourton property. The transaction involved the disposal of the asset for net proceeds of £1.7m and the immediate leaseback of the same asset under a 15 year lease.
|
Parent and ultimate parent undertaking |
The company's immediate parent is
The ultimate parent is
The most senior parent entity producing publicly available financial statements is